期刊文献+

1,25(OH)2D3口服冲击与血液灌流对维持性血液透析患者继发甲状旁腺功能亢进的疗效对比与护理 被引量:2

To compare clinical observation of efficacy of 1,25(OH)2D3 oral pulse and hemoperfusion cure secondary hyperparathyroidism in maintenance hemodialysis patients and nursing
下载PDF
导出
摘要 目的:比较1,25(OH)2D3口服冲击与血液灌流对维持性血液透析患者继发甲状旁腺功能亢进(SHPT)的疗效与护理。方法:将维持性血液透析SHPT患者42例随机分成A组[1,25(OH)2D3口服冲击组]及B组(血液灌流组)各21例。A组在1周3次血液透析治疗基础上给予1,25(OH)2D3口服冲击;B组给予1周3次血液灌流串联血液透析治疗。比较治疗后两组血清全段反应性甲状旁腺激素(iPTH)和皮肤瘙痒等改善情况,并探讨护理要点。结果:治疗12周后两组患者iPTH与治疗前相比具有显著性(P<0.01),但B组下降程度较A组更为显著(P<0.01)。结论:血液灌流对维持性血液透析患者SHPT的疗效比1,25(OH)2D3口服冲击更明显,且皮肤瘙痒等症状好转,值得临床推广。 Objective:To compare clinical observation of efficacy of 1,25(OH)2D3 oral pulse and hemoperfusion cure secondary hyperparathyroidism in maintenance hemodialysis patients and nursing.Methods:42 maintenance hemodialysis SHPT patients were radomly divided into group A[1,25(OH)2D3 oral pulse]21 cases and group B (hemoperfusion) 21 cases. Group A accepted 1,25(OH)2D3 oral pulse based hemodialysis three times a week,and group B accepted hemoperfusion and hemodialysis.After treatment to compare two sets of iPTH and pruritus and nursing points.Results:After treatment 12 weeks the iPTH in two groups has significant than before treatment(P〈0.01), but the decline degree of group B better than group A(P〈0.01). Conclusion:Hemoperfusion cure secondary hyperparathyroidism in maintenance hemodialysis patients better than 1,25(OH)2D3 oral pulse,improve pruritus, It is worth popularizing.
出处 《护理实践与研究》 2010年第13期23-24,共2页 Nursing Practice and Research
关键词 1 25(OH)2D3 血液灌流 继发甲状旁腺功能亢进 1 25(OH)2D3 Hemoperfusion Secondary hyperparathyroidism
  • 相关文献

参考文献6

二级参考文献19

  • 1魏守亮,张凌,陆文进.比较血液透析患者在不同PTH状态下低钙透析液的疗效[J].中国血液净化,2005,4(10):531-534. 被引量:10
  • 2邹贵勉,车文体,眭维国,刘作海.中药熏蒸治疗尿毒症患者顽固性瘙痒[J].中国血液净化,2006,5(1):56-57. 被引量:22
  • 3章俊,李幼姬,叶任高,李希杰.大剂量1,25(OH)_2D_3口服冲击治疗血透病人血清甲状旁腺素(1-84)异常的观察[J].中华肾脏病杂志,1996,12(2):86-88. 被引量:19
  • 4Ritz E,Matthias,Seidel A.Disturbed calcinm metabolism in renal failure-pathogenesis and therapeutic strategies[J].Kidney Intern,1992,42:38~40.
  • 5London G M, Marty R,Selovaggiolo M,et al. Arterial calcifications and bone histomorpbometry in end-stage renal disease[j]. J Am Soc Nephrol,2004,15:1 943-1 951.
  • 6Braneaccio D,Cozzoline M,Cailleni M. Hyperparathyroidism and anemia in uremic subieet: A combined therapeutic approaeh[J].J Am Sac Nephrol,2004,15(supp 1) ; 21,144.
  • 7Tan-Au J R,Lerine B S,Mazess R B,et al ,Effective suppression of parathyroid hormone by 1α-hydroxy-vitamine Dz in bemodialysis pafients with moderate to severe secondary hyperparathyroidism[J]. Kidney Int, 1997,51(1) : 317-323.
  • 8Tetta C,Callieni M,Panichi V,etal. Vascular caleifications as a footprim of increased caldum load and chronidnfiammafion in uriemic patients; A need for A natural caldum blanee during hemodialysis[J], hat J Artif Organs,2002,25(1) : 18-26.
  • 9Klassen PS,Lawrin G,Reddan DN,et al.Association between pulse pressure and morta1ity in patients undergoing maintenance hemodialysis[].The Journal of The American Medical Association.2002
  • 10Block GA,Port FK.Re-evaluation of risks associated with hy-perphosphatemia and hyperparathyroidsm in dialysis patients:Recommendations for a change in management[].American Journal of Kidney Diseases.2000

共引文献35

同被引文献13

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部